Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 3/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nornicotine SCHEMBL26098503 | 0.93 | LMNA (0.51) | LMNAKDM4EALDH1A1OPRK1OPRM1 | |
| SCHEMBL23747561 | 0.90 | NAMPT (0.57) | ALDH1A1OPRK1OPRM1NAMPTNPC1 | |
| SCHEMBL23747504 | 0.89 | NPC1 (0.60) | KDM4EALDH1A1OPRK1OPRM1MAPT | |
| SCHEMBL23747503 | 0.89 | NPC1 (0.60) | KDM4EALDH1A1OPRK1OPRM1MAPT | |
| SCHEMBL31029080 | 0.86 | LMNA (0.58) | LMNAKDM4EALDH1A1OPRK1OPRM1 | |
| SCHEMBL31043697 | 0.86 | LMNA (0.58) | LMNAKDM4EALDH1A1OPRK1OPRM1 | |
| SCHEMBL23747564 | 0.85 | NAMPT (0.53) | LMNAKDM4ENAMPTNPC1RAB9A | |
| SCHEMBL30361423 | 0.85 | NPC1 (0.60) | LMNAALDH1A1OPRK1OPRM1MAPT | |
| SCHEMBL26099386 | 0.85 | NPC1 (0.60) | LMNAALDH1A1OPRK1OPRM1MAPT | |
| SCHEMBL23747562 | 0.84 | NPC1 (0.63) | KDM4EALDH1A1OPRK1OPRM1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | LMNA 2810/4885KDM4E 2721/4885ALDH1A1 2019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.